Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

GERMANTOWN, Md., Jan. 30 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has closed its previously announced private placement of common stock and warrants, resulting in the receipt of $21 million in gross proceeds.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG(TM), its once-daily amoxicillin product, and for working capital and general corporate purposes.

The shares sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to institutional and accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the common stock issued in the private placement and issuable upon the exercise of the warrants.

This news release is not an offer to sell or the solicitation of an offer to buy the shares of the Company.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercial
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Research Institute (IDRI) announces today the appointment of H. ... new member of the IDRI board of directors.  Parker ... having served as President and CEO of Targeted Genetics ... Corp. "I look forward to working with ...
... FORT WORTH, Texas, Feb. 15, 2011 The Center ... Center recently received a three-year $3.5 million grant ... leader in forensic DNA testing systems, to train researchers ...  This first of its kind accelerated academic certification program ...
... 15, 2011 Neuralstem, Inc. (NYSE Amex: ... I. Westreich to its Board of Directors. With his ... majority of independent directors. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO) ... of Directors and the Company,s Chief Science Officer, welcomed ...
Cached Biology Technology:IDRI Announces Appointment of H. Stewart Parker as Chief Executive Officer 2$3.5 Million Life Technologies Grant Will Help Train, Certify Forensic Scientists at UNT Health Science Center 2$3.5 Million Life Technologies Grant Will Help Train, Certify Forensic Scientists at UNT Health Science Center 3$3.5 Million Life Technologies Grant Will Help Train, Certify Forensic Scientists at UNT Health Science Center 4Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 2Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstem's Board 3
(Date:4/17/2014)... to treat tuberculosis could be the basis for a ... fungal infections and parasites, yet evade resistance, according to ... , Led by U. of I. chemistry professor Eric ... SQ109 attacks the tuberculosis bacterium, how the drug can ... malaria and how targeting multiple pathways reduces the ...
(Date:4/17/2014)... a word for chili peppers. Information about archaeological remains ... study of the appearance of words for chili peppers ... were domesticated and highlight the value of multi-proxy data ... al.) of nine papers presented in a special feature ... of Sciences on plant and animal domestication edited ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
Breaking Biology News(10 mins):Multitarget TB drug could treat other diseases, evade resistance 2Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2
... Calif.) Calling the results "extremely surprising," researchers from ... University report that methane gas concentrations in the Gulf ... months after a massive release occurred following the Deepwater ... study, led by oceanographers John Kessler of Texas A&M ...
... team took a significant step forward in understanding ... pollutants and some other gases, except carbon dioxide. ... with some studies suggesting the self-cleaning power of ... changes, while others suggest greater stability. And what ...
... scientists "build" new biological systems, Princeton University scientists have ... the growth of living cells. The team of ... and the scientists showed that they can produce substances ... proteins produced by nature,s own toolkit. "What ...
Cached Biology News:UCSB, Texas A&M scientists find methane gas concentrations have returned to near-normal levels 2NOAA-led team measures atmosphere's self-cleaning capacity 2NOAA-led team measures atmosphere's self-cleaning capacity 3Princeton scientists construct synthetic proteins that sustain life 2Princeton scientists construct synthetic proteins that sustain life 3
... Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the fusion ... immunized (BALB/c X C57BL/6)F1 (CbyB6F1) ... mouse myeloma cellline. ...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: